Select Publications
Journal articles
2024, 'Comparison of isotype-specific nanobody enrichment with matrix-assisted laser desorption/ionisation-time of flight method with serum immunofixation electrophoresis in detection of paraproteins', Pathology, 56, pp. S111 - S112, http://dx.doi.org/10.1016/j.pathol.2023.12.370
,2023, 'Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses', Journal of Gastroenterology and Hepatology (Australia), 38, pp. 724 - 732, http://dx.doi.org/10.1111/jgh.16133
,2023, 'Serum protein electrophoresis and rheumatoid factor analysis is an effective screening strategy for cryoglobulinaemia', Pathology, 55, pp. 391 - 396, http://dx.doi.org/10.1016/j.pathol.2022.09.004
,2023, 'Monoclonal antibody interference in electrophoresis', Pathology, 55, pp. 163 - 165, http://dx.doi.org/10.1016/j.pathol.2022.05.014
,2022, 'Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children', Journal of Crohn's and Colitis, 16, pp. 1835 - 1844, http://dx.doi.org/10.1093/ecco-jcc/jjac093
,2021, 'Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency', Journal of Clinical Immunology, 41, pp. 1915 - 1935, http://dx.doi.org/10.1007/s10875-021-01141-0
,2021, 'Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol', BMJ open, 11, http://dx.doi.org/10.1136/bmjopen-2020-043921
,2021, 'Comparison of three commercially available ELISA assays for anti-infliximab antibodies', Pathology, 53, pp. 508 - 514, http://dx.doi.org/10.1016/j.pathol.2020.08.020
,2021, 'Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings', Internal Medicine Journal, 51, pp. 739 - 745, http://dx.doi.org/10.1111/imj.14644
,2020, 'Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies', Therapeutic Drug Monitoring, 42, pp. 821 - 828, http://dx.doi.org/10.1097/FTD.0000000000000795
,2020, 'Estimating urinary losses of rituximab in membranous nephropathy with nephrotic range proteinuria', Pathology, 52, pp. S41 - S41, http://dx.doi.org/10.1016/j.pathol.2020.01.149
,2019, 'Comparison of three commercially-available elisa assays for anti-infliximab antibodies', Pathology, 51, pp. S132 - S133, http://dx.doi.org/10.1016/j.pathol.2018.12.383
,2019, 'Monoclonal antibody interference in serum electrophoresis', Pathology, 51, pp. S67 - S67, http://dx.doi.org/10.1016/j.pathol.2018.12.156
,2018, 'Gastric Cancer Screening in Common Variable Immunodeficiency', Journal of Clinical Immunology, 38, pp. 768 - 777, http://dx.doi.org/10.1007/s10875-018-0546-3
,2017, 'Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases', Alimentary Pharmacology and Therapeutics, 46, pp. 1037 - 1053, http://dx.doi.org/10.1111/apt.14368
,2017, 'Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits: author reply', Pathology, 49, pp. 334 - 335, http://dx.doi.org/10.1016/j.pathol.2017.01.005
,2016, 'Comparison of infliximab drug measurement across three commercially available ELISA kits', Pathology, 48, pp. 608 - 612, http://dx.doi.org/10.1016/j.pathol.2016.07.001
,2015, 'Anti-synthetase syndrome associated with anti PL-12 and anti-Signal recognition particle antibodies and a necrotizing auto-immune myositis', Journal of Clinical Neuroscience, 22, pp. 396 - 398, http://dx.doi.org/10.1016/j.jocn.2014.04.031
,2014, '10. Anti-synthetase syndrome associated with necrotizing myositis – Utility of myositis specific autoantibodies in predicting prognosis and choice of treatment', Clinical Neurophysiology, 125, pp. e4 - e4, http://dx.doi.org/10.1016/j.clinph.2013.10.032
,2012, 'Phar lap and the filly: validating the anti-DSDNA-NCX IgG ELISA', Pathology, 44, pp. S69 - S69, http://dx.doi.org/10.1016/s0031-3025(16)32777-5
,2012, 'Use of cardiac MR imaging to evaluate the presence of myocarditis in autoimmune myositis: three cases', Rheumatology International, 32, pp. 779 - 782
,2011, 'Clearing the complexity: immune complexes and their treatment in lupus nephritis', International Journal of Nephrology and Renovascular Disease, 4, pp. 17 - 28, http://dx.doi.org/10.2147/IJNRD.S10233
,2009, 'Use of Cardiac MR Imaging to Evaluate the Presence of Myocarditis in Autoimmune Myositis: 3 Cases', Heart, Lung and Circulation, 18, pp. S59 - S59, http://dx.doi.org/10.1016/j.hlc.2009.05.130
,2007, 'Investigation of the patient with suspected allergy', Medicine Today, 8, pp. 49 - 56
,Conference Papers
2017, 'Biological level testing in inflammatory bowel disease identifies inappropriate use of infliximab, with substantial associated cost savings', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 132 - 133, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100240&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Secondary loss of response is the most common indication for infliximab level testing in inflammatory bowel disease: The Australian experience', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 153 - 154, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100273&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Therapeutic drug monitoring-guided biological drug therapy in inflammatory bowel disease: Consensus statements of the Australian Inflammatory Bowel Disease Association (AIBDA) and Gastroenterological Society of Australia (GESA)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 136 - 138, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100247&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'AN AETIOLOGY FOR IgG4 RELATED DISEASE?', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 22 - 22, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323685200066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Presentations
2013, 'A BRAF NEW WORLD', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323685200079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Abstracts
2022, 'PATIENT PERCEPTIONS OF HEALTH-RELATED QUALITY OF LIFE IN AN AUSTRALIAN ADULT PRIMARY IMMUNODEFICIENCY COHORT', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 52, pp. 27 - 27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862654200072&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'INFLIXIMAB DOSE INTENSIFICATION FOR SECONDARY LOSS OF RESPONSE IN IBD: UPFRONT INTENSIFICATION IS SIMILARLY EFFECTIVE TO DOSE INTERVAL SHORTENING WITH THE ADDED BENEFIT OF EARLY PREDICTORS OF RESPONSE', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, CA, San Diego, Vol. 162, pp. S810 - S810, presented at Digestive Disease Week (DDW), CA, San Diego, 21 May 2022 - 24 May 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826446203163&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'P462 Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in Journal of Crohn's and Colitis, Oxford University Press (OUP), Vol. 16, pp. i437 - i438, http://dx.doi.org/10.1093/ecco-jcc/jjab232.589
,2022, 'Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 16, pp. I437 - I438, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778573401167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 16, pp. I437 - I438, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778573400589&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Mo1541: INFLIXIMAB DOSE INTENSIFICATION FOR SECONDARY LOSS OF RESPONSE IN IBD: UPFRONT INTENSIFICATION IS SIMILARLY EFFECTIVE TO DOSE INTERVAL SHORTENING WITH THE ADDED BENEFIT OF EARLY PREDICTORS OF RESPONSE', in Gastroenterology, Elsevier BV, Vol. 162, pp. S - 810, http://dx.doi.org/10.1016/s0016-5085(22)61913-9
,2022, 'Serum protein electrophoresis and rheumatoid factor analysis as a screening strategy for cryoglobulinaemia', in Pathology, Elsevier BV, Vol. 54, pp. S82 - S82, http://dx.doi.org/10.1016/j.pathol.2021.12.267
,2021, 'STANDARDISED TESTING AND COMMUNICATION INCREASE BETA-LACTAM ALLERGY DELABELLING EFFECTIVENESS: RESULTS OF 'DE-LABELLING PATIENTS WITH ANTIBIOTIC ALLERGY IN SYDNEY ADULT AND PAEDIATRIC HOSPITALS'', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 51, pp. 13 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713717300029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'De-labelling patients with antibiotic allergy in Sydney adult and paediatric hospitals-towards standardisation and improved patient outcomes', in ALLERGY, WILEY, ENGLAND, London, Vol. 75, pp. 216 - 216, presented at European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), ENGLAND, London, 06 June 2020 - 08 June 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000566847300395&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'DE-LABELLING PATIENTS WITH ANTIBIOTIC ALLERGY IN SYDNEY ADULT AND PAEDIATRIC HOSPITALS- TOWARDS STANDARDISATION AND IMPROVED PATIENT OUTCOMES', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 49, pp. 15 - 15, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488891400038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'GASTRIC CANCER SCREENING IN COMMON VARIABLE IMMUNODEFICIENCY', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 48, pp. 27 - 27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449673000073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,